Drugs for Antiviral Combination Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 16377
Special Issue Editors
Interests: virus–host interaction; innate immunity; antiviral research; drug repurposing
Interests: interaction of influenza viruses and other respiratory pathogens with the host cells and immune system; innate immune mechanisms in acute virus infections; host-targeted antivirals against respiratory viruses
Special Issues, Collections and Topics in MDPI journals
Interests: host–pathogen interactions; host intracellular compartments; drug repurposing
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The host–virus interplay and host signaling cascades involved in the entry and propagation of novel and emerging viruses are far from being understood. Many direct-acting antivirals or host-directed drugs are currently under investigation to estimate their antiviral potential. Using more than one antiviral might potentiate the antiviral effect and preserve sensitivity to the drugs. A combination of drugs that target different steps of the virus life cycle is a promising clinical approach as already confirmed in HIV or HCV therapy. The scope of this Special Issue is to explore novel virus and cellular key sensors and effectors involved in virus infection as novel pharmacological targets, evaluate respective drugs, and assess their effects when given in combination.
We are looking forward to receiving your contributions.
Dr. Sebastian Schloer
Prof. Dr. Stephan Ludwig
Prof. Dr. Ursula Rescher
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antivirals
- virus-directed drugs
- host-directed drugs
- drug repurposing
- combination therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.